Logo

    tdf

    Explore " tdf" with insightful episodes like "Questions Answered on ART Safety and Tolerability in Pregnant People and Transgender Individuals", "21/02/23 "Perdonar..." - Dia 2", "27/01/23 Activando tu Fe - Dia 5", "26/01/23 Activando tu Fe - Dia 4" and "24/01/23 Activando tu Fe - Dia 2" from podcasts like ""CCO Infectious Disease Podcast", "Pastores Carlos y Karla Lopez", "Pastores Carlos y Karla Lopez", "Pastores Carlos y Karla Lopez" and "Pastores Carlos y Karla Lopez"" and more!

    Episodes (76)

    Questions Answered on ART Safety and Tolerability in Pregnant People and Transgender Individuals

    Questions Answered on ART Safety and Tolerability in Pregnant People and Transgender Individuals

    In this episode, Jill Blumenthal, MD, MAS, and William R. Short, MD, MPH, AAHIVS, address key considerations when evaluating ART safety and tolerability in pregnant people, those trying to conceive, and transgender individuals, such as:

    • Approaching patients trying to conceive on nonpreferred ART regimens (eg, 2-drug regimens like LA CAB and RPV)
    • Optimizing the use of the Antiretroviral Pregnancy Registry
    • Addressing unique barriers to ARV adherence in transgender individuals with HIV (eg, drug formulation considerations for ARV medications and gender-affirming hormone therapy, sperm banking or egg harvesting, drug coverage considerations)

    Faculty: 
    Jill Blumenthal, MD, MAS
    Associate Professor of Medicine
    Infectious Diseases and Global Public Health 
    University of California, San Diego
    San Diego, California

    William R. Short, MD, MPH, AAHIVS
    Associate Professor of Medicine
    Division of Infectious Diseases 
    Department of Medicine  
    Perelman School of Medicine at the University of Pennsylvania 
    Philadelphia, Pennsylvania

    Link to full program:
    http://bit.ly/3PM3nYe

    Link to downloadable slides: 
    http://bit.ly/3WgYycz

    Questions Answered on ART Safety and Tolerability in Aging Patients and Populations With Cardiometabolic Toxicities

    Questions Answered on ART Safety and Tolerability in Aging Patients and Populations With Cardiometabolic Toxicities

    In this episode, Marta Boffito, MD, PhD, FRCP, and Jens D. Lundgren, MD, DMSc, address key considerations when evaluating antiretroviral therapy safety and tolerability in aging patients and those with possible cardiometabolic toxicities, including:

    • Monitoring for cardiometabolic syndromes (eg, lipid panels, coronary artery calcification scores)
    • Approaching antiretroviral-related weight gain in clinical practice
    • Interpreting results from RESPOND on cardiovascular risk with integrase strand transfer inhibitors
    • Collaborating with other specialties (eg, cardiologists, dietitians) to provide a multidisciplinary approach for managing comorbidities, including prevention and management

    Faculty

    Marta Boffito, MD, PhD, FRCP
    Consultant Physician/Professor
    HIV/Research
    Chelsea and Westminster Hospital
    Imperial College London
    London, United Kingdom

    Jens D. Lundgren, MD, DMSc
    Professor
    Rigshospital, University of Copenhagen 
    Director
    Centre of Excellence for Health, Immunity and Infection (CHIP)
    Rigshospital, University of Copenhagen
    Copenhagen, Denmark

    Link to full program:
    http://bit.ly/3PM3nYe

    Link to downloadable slides: 
    http://bit.ly/3WgYycz

    Logo

    © 2024 Podcastworld. All rights reserved

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io